Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Two important updates regarding upcoming BARDA DRIVe funding opportunities:
Drive Special Instructions – Due May 28!
White papers, quad chart, and application form for the DRIVe special instructions to the BARDA BAA are due by 3:00 PM ET on Tuesday May 28th, 2019.
Focus areas are:
• 15.1: Advanced Research and Development of Sepsis Diagnostics and Devices
• 15.2: Post-sepsis Monitoring
• 16.1: On-Person, Wearable, and Biosensing Devices (Host Response and Direct Pathogen Detection)
Steps to apply:
1.Review Solicitation BAA-18-100-SOL-00003 on fbo.gov.
2.Schedule a meeting with the ENACT or Solving Sepsis team (strongly encouraged).
3.Download the DRIVe Special Instructions Submission Form.*
4.Complete the PDF form, Quad Chart, White Paper, and Addendum (ROM cost estimate).
5. Email your submission to DRIVeContracting@hhs.gov by 3:00PM ET on May 28th.
6. You will receive an email notification confirming receipt within 5 business days. DRIVe personnel will review your white paper as described in the solicitation.
7. DRIVe personnel will notify you of the outcome of that review and may invite you to submit a full proposal. *You must download the PDF, as filling it out in a browser window will disable some key functionality.
General DRIVe EZ-BAA – Deadline Extended
The deadline for DRIVe’s EZ-BAA has been extended to 3:00 PM ET on November 15th, 2019. Applications are reviewed on a rolling basis with a response as early as 30 days after submission.
DRIVe has a new online portal for submitting EZ-BAA. Note: Companies must register for a profile in the online portal here, it can take up to 1 business day to account to be created.
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => redesignation2025
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-21 14:51:44
[post_modified_gmt] => 2025-07-21 18:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4906
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4402
[post_author] => 3
[post_date] => 2024-03-01 12:43:19
[post_date_gmt] => 2024-03-01 17:43:19
[post_content] =>
Still time to register! Registration for the 8th annual Hack@CEWIT will close March 1 at 3pm.
Join hundreds of student hackers at the Center of Excellence in Wireless and Information Technology (CEWIT) for a 40-hour hackathon to learn new skills, make new connections, develop innovative ideas and compete for amazing prizes.
CEWIT will open its doors for the event at 5pm today. Do not miss your opportunity to Unleash Innovation and Transform Tomorrow
All participants must reside in the U.S and be currently registered in a college/university as an undergraduate, graduate, or PhD student.
[post_title] => Hack@CEWIT - Starts 3/1!
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => hackcewit-starts-3-1
[to_ping] =>
[pinged] =>
[post_modified] => 2024-03-01 12:43:20
[post_modified_gmt] => 2024-03-01 17:43:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4402
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2454
[post_author] => 4
[post_date] => 2016-11-15 21:24:24
[post_date_gmt] => 2016-11-15 21:24:24
[post_content] => The i6 Challenge award sets aim on enhancing Long Island Bioscience Ecosystem
The Center for Biotechnology at Stony Brook University has announced that is has received a three-year, $500,000 U.S. Department of Commerce i6 Challenge Investment. The award will support the Center for Biotechnology’s (CFB) efforts to bolster the regional bioscience ecosystem by supporting a formal mentorship program, as well as a critical NIH-focused SBIR/STTR training and application development program which will assist in capital formation and launching new companies.
The Center for Biotechnology is among 35 organizations — including nonprofits, institutions of higher education, and entrepreneurship-focused organizations — from 19 states that will receive nearly $15 million to create and expand cluster-focused, proof-of-concept and commercialization programs, and early-stage seed capital funds through the Economic Development Administration’s (EDA) Regional Innovation Strategies (RIS) program. The Office of Innovation and Entrepreneurship (OIE), housed within the U.S. Department of Commerce’s Economic Development Administration (EDA), leads the Regional Innovation Strategies Program to spur innovation capacity-building activities in regions across the nation.
“Long Island’s innovation economy is rooted in cutting-edge basic and applied science and engineering, fostered by top-tier research institutions, a highly educated population, and a depth, breadth and scope of intellectual capital.” said Dr. Clinton T. Rubin, Director, Center for Biotechnology. Dr. Rubin continued, “This award and the initiatives it will support add to the growing, concentrated efforts the Center for Biotechnology, the Long Island Bioscience Hub and the hub’s partner institutions are making to grow the high technology innovations born in our region into fully realized ventures.”
The Center for Biotechnology (CFB) at Stony Brook University is an Empire State Development Division of Science, Technology and Innovation (NYSTAR) Center for Advanced Technology. Established in 1983, the CFB’s efforts are focused on accelerating the development of biomedical technologies in order to have a positive impact on human health and society. The CFB is also the lead administrative institution for the Long Island Bioscience Hub (LIBH) an NIH-designated Research Evaluation and Commercialization Hub (REACH) established with a National Institutes of Health grant in 2015. The initiatives under the i6 Challenge award will complement the efforts of the LIBH, a partnership between the Center for Biotechnology, Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory and the Feinstein Institute for Medical Research, to commercialize biomedical innovations emerging from the partner institutions.
Download a PDF of the press release here.Related Articles:Schumer: Biz-Development Funds Big Deal For SBU - Innovate Long Island
Stony Brook Biotech Center Wins $500,000 to Foster Companies - Newsday
[post_title] => Center For Biotechnology Awarded $500k U.S. Department of Commerce Grant
[post_excerpt] => The Center for Biotechnology has received a three-year, $500,000 U.S. Department of Commerce i6 Challenge Investment to support efforts to bolster the regional bioscience ecosystem.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => center-for-biotechnology-awarded-500k-u-s-department-of-commerce-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2017-03-15 13:47:39
[post_modified_gmt] => 2017-03-15 13:47:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2454
[menu_order] => 158
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 1391
[post_author] => 3
[post_date] => 2015-02-05 13:34:47
[post_date_gmt] => 2015-02-05 13:34:47
[post_content] => The Center for Biotechnology at Stony Brook University has announced the appointment of Mohan Chellani, PhD, and Michael Bielski, MS, JD to the position of BioEntrepreneurs-In-Residence (B-EIR). Both Dr. Chellani and Mr. Bielski have extensive bioscience industry experience at the senior management level, and have successfully commercialized multiple academic innovations. Their roles as BEIRs is to identify technologies that have the potential to support company formation in the region. Each brings unique skills and perspectives to technology assessment and bioscience-startups.
Dr. Chellani has over twenty years of experience in the diagnostics industry prior to his
appointment as B-EIR, having served as VP, Scientific Affairs at Enzo Biochem, and as a
Director and Advisor to Quest Diagnostics. He has also served as founder and CEO of two startup companies, Progen Life Sciences and Discitis Diagnostics. Dr. Chellani holds a PhD in Biochemistry and Molecular Biology from UMD-New Jersey and an MBA from Fordham University.
Mr. Bielski has founded multiple technology companies, including co-founding NewLeaf Symbiotics, Inc., an agricultural biotechnology company that has raised over $25M in venture capital. He also served as the Assistant Director for Science and Technology Commercialization at the Center for Biotechnology for six years prior to pursuing his entrepreneurial ventures. Mr. Bielski holds a JD and an MS in Neuroscience from Syracuse University.
Both Dr. Chellani and Mr. Bielski will conduct due diligence to identify a technology or
technologies around which they may build a company. If successful, they will also be provided with access to a technology development budget that will help them position the technology for commercialization. B-EIRs also have access to the Center's business and technology development support staff to help develop appropriate business strategies. Ultimately, the goal is to help the company prepare for SBIR/STTR grant opportunities, and Angel and VC investment.
Read the full press release.
[post_title] => Center for Biotechnology Continues to Expand B-EIR Program
[post_excerpt] => Diagnostics Executive Mohan Chellani and Entrepreneur Michael Bielski
selected to evaluate emerging SBU technologies
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => center-for-biotech-continues-to-expand-b-eir-program
[to_ping] =>
[pinged] =>
[post_modified] => 2023-05-13 16:06:55
[post_modified_gmt] => 2023-05-13 16:06:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1391
[menu_order] => 215
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 5
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4906
[post_author] => 4
[post_date] => 2025-07-17 10:27:09
[post_date_gmt] => 2025-07-17 14:27:09
[post_content] =>
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
